Antibody–drug conjugates (ADCs) have long been pursued to improve cure rates in these malignancies, with a major focus on CD33 (for acute myeloid leukemia [AML]) and CD22 (for B-acute lymphoblastic leukemia [B-ALL]). This evidence concerns the gene CD22 and acute lymphoblastic leukemia.